Si-bone, INC 8-K filings

SI-BONE, Inc. reported robust second quarter 2026 financial results, including ~15% worldwide revenue growth and a significant increase in adjusted EBITDA, leading to an upward revision of its full-year guidance.

SI-BONE, Inc. has amended its lease for its Santa Clara headquarters, extending the term through August 31, 2026, with an option for an additional month, and has reported the outcomes of its annual shareholder meeting, including director elections and auditor ratification.

SI-BONE, Inc. announced first quarter 2026 financial results, showcasing 11.2% worldwide revenue growth and a significant improvement in adjusted EBITDA, leading to an upward revision of its full-year guidance.

SI-BONE, Inc. announced record financial results for Q4 and full year 2025, achieving over 20% worldwide revenue growth and positive adjusted EBITDA, alongside new 2026 guidance and key operational updates.

SI-BONE, Inc. announced preliminary unaudited revenue and cash for Q4 and full year 2025, showing robust growth and net cash generation.

SI-BONE, Inc. reported strong third-quarter 2025 financial results with significant revenue growth and improved profitability, leading to an upward revision of its full-year 2025 guidance.

SI-BONE, Inc. reported strong second-quarter 2025 financial results with significant revenue growth and positive Adjusted EBITDA, leading to raised full-year guidance.

SI-BONE, Inc. announced the successful election of its proposed directors, ratification of its independent auditor, and advisory approval of executive compensation at its recent Annual Meeting.

SI-BONE, Inc. announced a robust first quarter in 2025 with significant revenue growth and positive adjusted EBITDA, leading to an updated and improved full-year revenue guidance.

SI-BONE announces strong Q4 2024 results with 26% worldwide revenue growth and positive adjusted EBITDA, alongside promising 2025 financial guidance.

SI-BONE reports preliminary unaudited revenue growth of approximately 26% for the fourth quarter of 2024 and achieves adjusted EBITDA profitability.

SI-BONE, Inc. announced a strong third quarter with significant revenue growth and a substantial improvement in adjusted EBITDA, expecting to achieve profitability in the fourth quarter of 2024.

SI-BONE, Inc. announced a 20% year-over-year revenue increase for Q2 2024, raised its full-year revenue guidance, and anticipates achieving positive adjusted EBITDA in Q4 2024.

SI-BONE, Inc. has extended its office lease in Santa Clara, California, for an additional 14 months, securing its corporate headquarters through July 2026.

SI-BONE, Inc. stockholders approved an amendment to the company's charter to limit the liability of certain officers at the 2024 Annual Meeting.

SI-BONE, Inc. announced a 16% increase in worldwide revenue for Q1 2024 and raised its full-year revenue guidance to $164-$166 million.

SI-BONE, a medical device company, announced record full-year revenue growth of 31% in 2023 and provided a positive revenue outlook for 2024.